Biological variation of cardiac troponins in chronic kidney disease
Author
Jones, R ABarratt, J
Brettell, E A
Cockwell, P
Dalton, R N
Deeks, J J
Eaglestone, G
Pellatt-Higgins, T
Kalra, P A
Khunti, K
Morris, F S
Ottridge, R S
Sitch, A J
Stevens, P E
Sharpe, C C
Sutton, A J
Taal, M W
Lamb, E J
Affiliation
East Kent Hospitals University NHS Foundation Trust; University Hospitals of Leicester; University of Birmingham; University Hospitals Birmingham NHS Foundation Trust; Evelina London Children's Hospital; Test Evaluation Research Group; University of Kent; Salford Royal NHS Foundation Trust; University of Leicester; King's College London; King's College Hospital NHS Foundation Trust; Institute of Health Economics, Canada; University of Nottingham; Royal Derby HospitalPublication date
2020-02-27
Metadata
Show full item recordAbstract
Background Patients with chronic kidney disease often have increased plasma cardiac troponin concentration in the absence of myocardial infarction. Incidence of myocardial infarction is high in this population, and diagnosis, particularly of non ST-segment elevation myocardial infarction (NSTEMI), is challenging. Knowledge of biological variation aids understanding of serial cardiac troponin measurements and could improve interpretation in clinical practice. The National Academy of Clinical Biochemistry (NACB) recommended the use of a 20% reference change value in patients with kidney failure. The aim of this study was to calculate the biological variation of cardiac troponin I and cardiac troponin T in patients with moderate chronic kidney disease (glomerular filtration rate [GFR] 30–59 mL/min/1.73 m2). Methods and results Plasma samples were obtained from 20 patients (median GFR 43.0 mL/min/1.73 m2) once a week for four consecutive weeks. Cardiac troponin I (Abbott ARCHITECT® i2000SR, median 4.3 ng/L, upper 99th percentile of reference population 26.2 ng/L) and cardiac troponin T (Roche Cobas® e601, median 11.8 ng/L, upper 99th percentile of reference population 14 ng/L) were measured in duplicate using high-sensitivity assays. After outlier removal and log transformation, 18 patients’ data were subject to ANOVA, and within-subject (CVI), between-subject (CVG) and analytical (CVA) variation calculated. Variation for cardiac troponin I was 15.0%, 105.6%, 8.3%, respectively, and for cardiac troponin T 7.4%, 78.4%, 3.1%, respectively. Reference change values for increasing and decreasing troponin concentrations were +60%/–38% for cardiac troponin I and +25%/–20% for cardiac troponin T. Conclusions The observed reference change value for cardiac troponin T is broadly compatible with the NACB recommendation, but for cardiac troponin I, larger changes are required to define significant change. The incorporation of separate RCVs for cardiac troponin I and cardiac troponin T, and separate RCVs for rising and falling concentrations of cardiac troponin, should be considered when developing guidance for interpretation of sequential cardiac troponin measurements.Citation
Jones RA, Barratt J, Brettell EA, Cockwell P, Dalton RN, Deeks JJ, Eaglestone G, Pellatt-Higgins T, Kalra PA, Khunti K, Morris FS, Ottridge RS, Sitch AJ, Stevens PE, Sharpe CC, Sutton AJ, Taal MW, Lamb EJ; eGFR-C Study Group. Biological variation of cardiac troponins in chronic kidney disease. Ann Clin Biochem. 2020 Mar;57(2):162-169. doi: 10.1177/0004563220906431. Epub 2020 Feb 27.Type
ArticleAdditional Links
https://journals.sagepub.com/home/ACBPMID
32024371Journal
Annals of Clinical BiochemistryPublisher
Sageae974a485f413a2113503eed53cd6c53
10.1177/0004563220906431